AU Patent

AU2015217788B2 — Benzimidazol-2-amines as mIDH1 inhibitors

Assigned to Deutsches Krebsforschungszentrum DKFZ · Expires 2019-06-27 · 7y expired

What this patent protects

The present invention relates to benzimidazol-2-amines of general formula (I), in which R

USPTO Abstract

The present invention relates to benzimidazol-2-amines of general formula (I), in which R

Drugs covered by this patent

Patent Metadata

Patent number
AU2015217788B2
Jurisdiction
AU
Classification
—
Expires
2019-06-27
Drug substance claim
No
Drug product claim
No
Assignee
Deutsches Krebsforschungszentrum DKFZ
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.